HC2's Pansend Life Sciences Segment Is Focused on the Development
of Innovative Healthcare Technologies and Products

  • 80% equity ownership of company focused on immunotherapy; Oncolytic virotherapy for treatment of solid cancer tumors
  • Founded by Dr. Matthew Mulvey & Dr. Ian Mohr (who co-developed T-Vec); Biovex (owner of T-Vec) acquired by Amgen for ~$1billion
  • Benevir's T-Stealth is a second generation oncolytic virus with new features and new intellectual property
  • BeneVir holds exclusive worldwide license to develop BV-2711 (T-Stealth)
  • Granted new patent entitled "Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof", covering the composition of matter for Stealth-1H, Benevir's lead oncolytic immunotherapy, as well as other platform assets (2Q17)
  • 71% equity ownership of dermatology company focused on lightening and brightening skin
  • Founded by Pansend in partnership with Mass. General Hospital and inventors Drs. Rox Anderson, Dieter Manstein and Henry Chan
  • Over $20 billion global market
  • Received Food and Drug Administration (FDA) approval for the R2 Dermal Cooling System (4Q16)
  • 77% equity ownership in company with unique knee replacements based on technology from Dr. Peter Walker, NYU Dept. of Orthopedic Surgery and one of the pioneers of the original Total Knee
  • "Mini-Knee" for early osteoarthritis of the knee; "Anatomical Knee" — A Novel Total Knee Replacement
  • Strong patent portfolio
  • 45% equity ownership in company with unique technology and device for monitoring of real-time kidney function
  • Current standard diagnostic tests measure kidney function are often inaccurate and not real-time
  • MediBeacon's Optical Renal Function Monitor will be first and only, non-invasive system to enable real-time, direct monitoring of renal function at point-of-care
  • $3.5 billion potential market
  • Successfully completed a key clinical study of its unique, real-time kidney monitoring system on subjects with impaired kidney function at Washington University in St. Louis. (1Q17)
  • Profitable technology and product development company
  • Areas of expertise include medical devices , homeland security, imaging systems, sensors, optics, fluidics, robotics and mobile healthcare
  • Located in Silicon Valley and Boston area with over 90,000 square feet of working laboratory and incubator space
  • Contract R&D market growing rapidly
  • Customers include Fortune 500 companies and start-ups

*HC2 ownership positions as of March 31, 2017

Leave a Reply

Your email address will not be published. Required fields are marked *
You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>